Bobby Gaspar - 01 Mar 2023 Form 4 Insider Report for Orchard Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ Frank E. Thomas, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 17:00:13 UTC
Previous filing
06 Oct 2022
Next filing
24 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORTX Stock Option (Right to Buy) Award $0 +563,410 $0.000000 563,410 01 Mar 2023 Ordinary Shares 563,410 $0.4636 Direct F1, F2
transaction ORTX Stock Option (Right to Buy) Award $0 +581,590 $0.000000 581,590 01 Mar 2023 Ordinary Shares 581,590 $0.5795 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2023.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.